2025-04-16 - Analysis Report
## Intuitive Surgical Inc. (ISRG) Stock Report

**0. Key Figures:**

* **Cumulative Return (ISRG):** 111.39%
* **Cumulative Return (VOO/S&P 500):** 66.27%
* **Return Difference:** 45.1%
* **Relative Divergence:** 40.4% (Indicates ISRG's performance is in the top 40.4% of its historical range relative to the S&P 500)
* **Current Price:** $488.27
* **Market Risk Indicator (MRI):** 0.4175 (Medium Risk)


**1. Company Overview and Performance Comparison:**

Intuitive Surgical Inc. is a leading developer and manufacturer of robotic-assisted surgery systems.  Over the reviewed period, ISRG significantly outperformed the S&P 500 (VOO), exhibiting a cumulative return of 111.39% compared to VOO's 66.27%. This represents a substantial outperformance of 45.1 percentage points.  The relative divergence of 40.4% suggests this outperformance is relatively high compared to its historical performance relative to the S&P 500.

The provided Alpha and Beta analysis shows variable performance over time, with high CAGR (Compound Annual Growth Rate) in some periods and negative returns in others. Alpha values generally indicate outperformance against the benchmark, although this varies across the periods reviewed. Beta values show varying levels of market sensitivity.


**Alpha, Beta Analysis:**

| Year       | CAGR | MDD  | Alpha | Beta | Cap(B) |
|------------|------|------|-------|------|-------|
| 2015-2017  | 68.0% | 56.5% | 38.0% | 0.0 | 43.6 |
| 2016-2018  | 77.0% | 63.4% | 60.0% | 0.0 | 57.2 |
| 2017-2019  | 81.0% | 63.4% | 52.0% | 0.3 | 70.6 |
| 2018-2020  | 47.0% | 63.4% | 22.0% | 0.2 | 97.7 |
| 2019-2021  | 91.0% | 63.0% | 37.0% | 0.3 | 128.7 |
| 2020-2022  | -3.0% | 69.9% | -9.0% | 0.3 | 95.1 |
| 2021-2023  | -5.0% | 72.9% | -22.0% | 1.0 | 120.9 |
| 2022-2024  | 26.0% | 72.9% | 9.0% | 1.0 | 187.0 |
| 2023-2025  | 32.0% | 72.9% | 18.0% | 0.6 | 174.9 |


**2. Recent Price Movement:**

* **Closing Price:** $488.27
* **5-Day Moving Average:** $496.89
* **20-Day Moving Average:** $493.21
* **60-Day Moving Average:** $541.27

The stock price is currently below all three moving averages, suggesting a potential downward trend.  The recent closing price is slightly lower than the previous close, indicating a small daily decline.

**3. Technical Indicators and Expected Return:**

* **Market Risk Indicator (MRI):** 0.4175 (Medium Risk)
* **RSI:** 45.15 (Slightly below neutral; could indicate further downward movement)
* **PPO:** 0.5493 (Positive, suggesting bullish momentum)
* **20-Day Relative Divergence Change:** -11.1% (Short-term bearish trend)
* **Expected Return (vs. S&P 500):** 55.4% (Long-term, 2+ years)

The price change of -$0.38 reflects a relatively minor price decline and does not indicate a significant event like a sudden drop or surge. The long-term expected return significantly exceeds the S&P 500, reinforcing the potential for long-term investment.


**4. Recent Earnings Analysis:**

| Date       | EPS  | Revenue      |
|------------|------|---------------|
| 2024-10-18 | $1.59 | $2.04B        |
| 2024-07-19 | $1.48 | $2.01B        |
| 2024-04-19 | $1.54 | $1.89B        |
| 2023-10-20 | $1.18 | $1.74B        |
| 2024-10-18 | $1.18 | $1.74B       | *(Duplicate Entry - likely an error)*

Earnings have shown some fluctuation, but generally trend upwards with revenue consistently above $1.8B.  The duplicate entry needs clarification.


**5. Financial Information:**

**Revenue and Profitability:**

| Quarter | Revenue | Profit Margin |
|---------|----------|---------------|
| 2024-12-31 | $2.41B | 68.04% |
| 2024-09-30 | $2.04B | 67.41% |
| 2024-06-30 | $2.01B | 68.30% |
| 2024-03-31 | $1.89B | 65.87% |
| 2023-12-31 | $1.93B | 66.24% |

Revenue shows a strong upward trend, with profit margins remaining consistently high, indicating strong profitability.

**Capital and Profitability:**

| Quarter | Equity    | ROE     |
|---------|-----------|---------|
| 2024-12-31 | $16.43B  | 4.17%   |
| 2024-09-30 | $15.58B  | 3.63%   |
| 2024-06-30 | $14.71B  | 3.58%   |
| 2024-03-31 | $13.96B  | 3.90%   |
| 2023-12-31 | $13.31B  | 4.56%   |

Equity is growing steadily, while ROE (Return on Equity) shows some fluctuation but remains generally positive.


**6. Overall Analysis:**

ISRG has demonstrated significant outperformance compared to the S&P 500 over the long term, supported by strong revenue and profitability. However, recent price movements suggest a potential short-term bearish trend.  The medium-level Market Risk Indicator warrants cautious optimism.  The high long-term expected return, coupled with robust financial fundamentals, makes ISRG a potentially attractive investment for long-term investors comfortable with moderate risk.  Further investigation is recommended to clarify the duplicate entry in the earnings data.  Consideration should also be given to current market conditions and potential risks specific to the medical technology sector.
